Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced today that members of its management team will participate in one-on-one meetings at BTIG’s Infectious Disease Day 2026, a virtual event scheduled for June 16, 2026. Seth Lederman, M.D., president and chief executive officer of Tonix Pharmaceuticals, will represent the company during the event. The announcement comes as the fully integrated commercial-stage biotechnology company continues to advance its pipeline of central nervous system (CNS) and immunology treatments in areas of high unmet medical need.
Tonix’s participation in the BTIG conference underscores the importance of its immunology programs, which include monoclonal antibodies for infectious diseases. Among these is TNX-4800, a monoclonal antibody candidate for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection. These programs are part of a broader strategy to address critical gaps in infectious disease treatment and transplant medicine.
The company’s CNS portfolio remains a key focus, anchored by TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia approved in more than 15 years. Tonix is currently evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, potentially expanding its therapeutic reach. Additionally, the CNS pipeline includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder.
Tonix’s commercial infrastructure supports its marketed acute migraine products, Zembrace SymTouch and Tosymra. The company’s ability to bring TONMYA to market demonstrates its capacity to navigate regulatory pathways and deliver novel therapies to patients. The BTIG event provides an opportunity for investors to engage directly with management and gain insights into the company’s strategic direction.
The significance of this event lies in Tonix’s positioning at the intersection of CNS and immunology innovation. With the recent approval of TONMYA, the company has established a commercial foothold while simultaneously advancing a pipeline that addresses both rare diseases and common conditions. The virtual format of the conference allows for broader participation, enabling a wider range of stakeholders to learn about the company’s progress.
For more information about Tonix Pharmaceuticals, visit the company’s newsroom at https://ibn.fm/TNXP. The full press release regarding the BTIG event is available at https://ibn.fm/38XUG.
